Synonyms: Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2
ranibizumab is an approved drug (FDA (2006), EMA (2007))
Compound class:
Antibody
Comment: Ranibizumab is a Fab fragment of a monoclonal antibody designed to target vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody derivative are available from its IMGT/mAb-DB record. Peptide sequence analysis reveals that ranibizumab sequences are claimed in patent WO1998045331 (clone Y0317) [2], with an expected affinity similar to clone Y0313-1. It is the Fab fragment of bevacizumab. Biosimilars: Patent protection for originator ranibizumab is expected to expire in 2020 in the US and 2022 in the EU, and biosimilar development is well underway [4]. Intas Pharmaceuticals launched their Razumab® biosimilar in India in 2015. Samsung Bioepis' SB11 (Byooviz®, ranibizumab-nuna) was EMA approved in August 2021 (FDA approval followed in September 2021), following completion of NCT03150589 [5]. Genentech/Roche's biosimilar Susvimo® (in a refillable ranibizumab-containing ocular implant) was FDA approved for wet AMD in October 2021. Coherus BioSciences announced FDA approval for their biosimilar Cimerli® (ranibizumab-eqrn; formerly FYB201) in August 2022. Cimerli® can be prescribed for all five of the indications for which the reference product is authorised. |
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes (FDA (2006), EMA (2007)) |
International Nonproprietary Names ![]() |
|
INN number | INN |
8313 | ranibizumab |
Synonyms ![]() |
Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2 |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 84 |
Reactome Drug
![]() |
R-ALL-9679464 |
Reactome Reaction
![]() |
R-HSA-9679477 |
Other databases | |
GtoPdb PubChem SID | 178103385 |
PubChem SID | 178103385 |
Search PubMed clinical trials | ranibizumab |
Search PubMed titles | ranibizumab |
Search PubMed titles/abstracts | ranibizumab |
Wikipedia | Ranibizumab |